RU2016147122A - Применение серелаксина для снижения gdf-15 - Google Patents
Применение серелаксина для снижения gdf-15 Download PDFInfo
- Publication number
- RU2016147122A RU2016147122A RU2016147122A RU2016147122A RU2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A
- Authority
- RU
- Russia
- Prior art keywords
- serelaxin
- patient
- biological sample
- gdf
- administered
- Prior art date
Links
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 title claims 16
- 229960002792 serelaxin Drugs 0.000 title claims 16
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title claims 8
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title claims 8
- 238000000034 method Methods 0.000 claims 16
- 239000012472 biological sample Substances 0.000 claims 11
- 210000002966 serum Anatomy 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010037368 Pulmonary congestion Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011744P | 2014-06-13 | 2014-06-13 | |
| US62/011,744 | 2014-06-13 | ||
| PCT/IB2015/054399 WO2015189790A1 (en) | 2014-06-13 | 2015-06-10 | Use of serelaxin to reduce gdf-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016147122A true RU2016147122A (ru) | 2018-07-16 |
| RU2016147122A3 RU2016147122A3 (https=) | 2019-01-28 |
Family
ID=53476944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147122A RU2016147122A (ru) | 2014-06-13 | 2015-06-10 | Применение серелаксина для снижения gdf-15 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170100460A1 (https=) |
| EP (1) | EP3154559B1 (https=) |
| JP (1) | JP6820748B2 (https=) |
| KR (1) | KR20170018829A (https=) |
| CN (1) | CN106413740A (https=) |
| AU (2) | AU2015273097A1 (https=) |
| BR (1) | BR112016028833A2 (https=) |
| CA (1) | CA2952061A1 (https=) |
| MX (1) | MX2016016414A (https=) |
| RU (1) | RU2016147122A (https=) |
| WO (1) | WO2015189790A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| WO2015077540A2 (en) | 2013-11-21 | 2015-05-28 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| CN106794233B (zh) * | 2014-08-01 | 2021-11-12 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
| HK1256638A1 (zh) | 2015-08-04 | 2019-09-27 | Acceleron Pharma Inc. | 用於治疗骨髓增生性病症的方法 |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| CN114025675A (zh) * | 2019-06-20 | 2022-02-08 | 索尼集团公司 | 信息处理装置、信息处理方法和程序 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511656T1 (de) * | 2006-08-04 | 2011-06-15 | Hannover Med Hochschule | Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis |
| ES2379104T3 (es) * | 2007-05-24 | 2012-04-20 | F. Hoffmann-La Roche Ag | Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15 |
| CN102036679A (zh) * | 2008-05-16 | 2011-04-27 | 科尔泰拉公司 | 用松弛素治疗与急性心力衰竭相关的呼吸困难 |
| EP2726502A1 (en) * | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
-
2015
- 2015-06-10 CN CN201580032028.6A patent/CN106413740A/zh not_active Withdrawn
- 2015-06-10 JP JP2016572697A patent/JP6820748B2/ja not_active Expired - Fee Related
- 2015-06-10 US US15/316,952 patent/US20170100460A1/en not_active Abandoned
- 2015-06-10 WO PCT/IB2015/054399 patent/WO2015189790A1/en not_active Ceased
- 2015-06-10 RU RU2016147122A patent/RU2016147122A/ru not_active Application Discontinuation
- 2015-06-10 BR BR112016028833A patent/BR112016028833A2/pt not_active Application Discontinuation
- 2015-06-10 AU AU2015273097A patent/AU2015273097A1/en not_active Abandoned
- 2015-06-10 CA CA2952061A patent/CA2952061A1/en not_active Abandoned
- 2015-06-10 KR KR1020167034407A patent/KR20170018829A/ko not_active Withdrawn
- 2015-06-10 MX MX2016016414A patent/MX2016016414A/es unknown
- 2015-06-10 EP EP15730858.6A patent/EP3154559B1/en not_active Not-in-force
-
2018
- 2018-03-29 AU AU2018202289A patent/AU2018202289A1/en not_active Abandoned
- 2018-09-21 US US16/137,770 patent/US20190022189A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2952061A1 (en) | 2015-12-17 |
| EP3154559A1 (en) | 2017-04-19 |
| BR112016028833A2 (pt) | 2017-08-22 |
| MX2016016414A (es) | 2017-04-10 |
| US20190022189A1 (en) | 2019-01-24 |
| EP3154559B1 (en) | 2021-09-01 |
| US20170100460A1 (en) | 2017-04-13 |
| RU2016147122A3 (https=) | 2019-01-28 |
| JP2017519008A (ja) | 2017-07-13 |
| JP6820748B2 (ja) | 2021-01-27 |
| KR20170018829A (ko) | 2017-02-20 |
| AU2015273097A1 (en) | 2016-11-17 |
| AU2018202289A1 (en) | 2018-04-26 |
| WO2015189790A1 (en) | 2015-12-17 |
| CN106413740A (zh) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| McEwan et al. | Autocrine regulation of wound healing by ATP release and P2Y2 receptor activation | |
| Grodin et al. | Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF | |
| JP2017519008A5 (https=) | ||
| EA201892347A1 (ru) | Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов | |
| EA201390543A1 (ru) | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат | |
| Batal et al. | Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving≤ 2 years and those surviving≥ 5 years after baseline right-sided cardiac catheterization | |
| Stefaniak et al. | Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation | |
| EP4552696A3 (en) | Methods for predicting drug responsiveness in cancer patients | |
| de Almeida Faro et al. | Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia | |
| Turgut et al. | CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival | |
| Nicola et al. | Management of hypertension in chronic kidney disease: the Italian multicentric study | |
| Ehrnthaller et al. | Alteration of complement hemolytic activity in different trauma and sepsis models | |
| Gores et al. | Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy | |
| Bonella et al. | C42 SEARCHIN'FOR A CURE: NEW ILD TREATMENTS: Serum Kl-6 Levels Correlate With Response To Pirfenidone In Idiopathic Pulmonary Fibrosis | |
| Perfetti et al. | Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome | |
| Mayor | New blood marker can detect chronic kidney disease, study shows | |
| Leclerc et al. | Persistence of antibodies to infliximab for more than two months predicts loss of response to infliximab in inflammatory bowel diseases | |
| Mikacenic et al. | B24 MECHANISMS OF INJURY IN SEPSIS: INFLAMMATION, OXIDATION, AND ENDOTHELIAL DAMAGE: Biomarkers Of Endothelial Activation And Apoptosis Are Associated With Poor Outcomes In Critical Illness | |
| Yadav et al. | B47 ACUTE RESPIRATORY DISTRESS SYNDROME: Postoperative Acute Respiratory Distress Syndrome Is Associated With A Distinct Biomarker Profile: A Case Control Study | |
| Kendrick et al. | S78 Lymphopaenia and increased ace levels stratify sarcoidosis patients to underlying increase in IFN-γ+ lymphocyte and TNF-α+ monocytes respectively | |
| Vaes et al. | Longitudinal changes in regular physical activity (PA) in subjects with and without COPD: Findings from the Copenhagen City heart study | |
| Do Amaral et al. | D38 UPDATE IN ALPHA ONE DEFICIENCY: Replacement Of Alpha-1-Antitrypsin (aat) Biweekly In Brazilian Patients With Chronic Obstructive Pulmonary Disease (COPD) | |
| Uzaslan et al. | D44 COPD: TREATMENT FROM BRONCHODILATORS TO OTHER PHARMACOLOGICAL INTERVENTIONS: How Ageing Effects Hospitalization In Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease? | |
| Muthiah et al. | Left Ventricular Assist Devices in Patients with Hypertrophic Cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190610 |